Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity

International Journal of Hematology

Volumn 65, Issue 3, 1997, Pages 285-291

  Ninomiya, Haruhiko ^a   Hasegawa, Yuichi ^a   Nagasawa, Toshiro ^a   Abe, Tsukasa ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

CD87; Paroxysmal nocturnal hemoglobinuria; Thrombosis; Urokinase type plasminogen activator receptor

Indexed keywords

PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; LEUKOCYTE; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; THROMBOSIS;

EID: 0031127996     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(96)00559-2     Document Type: Article

References (40)

1. [1] Rosse WF. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 1990;75:1595-1601.
2. [2] Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86:3277-3286.
3. [3] Takeda J, Miyata T, Kawagoe K et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-711.
4. [4] Miyata T, Takeda J, Iida Y et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-1320.
5. [5] Bessler M, Mason PJ, Hillmen P et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994;13:110-117.
6. [6] Rotoli B, Luzzatto L. Paroxysmal nocturnal hemoglobinuria. Semin Haematol 1989;26:201-207.
7. [7] Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-1258.
8. [8] Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and response of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993;82:1192-1196.
9. [9] Ploug M, Plesner T, Rønne E et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992;79:1447-1455.
10. [10] Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriever L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
11. [11] Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988;4:93-126.
12. [12] Vassalli J-D, Baccino D, Belin D. A cellular binding site for the Mr 55000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
13. [13] Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266:1926-1933.
14. [14] Ploug M, Eriksen J, Plesner T, Hansen NE, Danø K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 1992;208:397-404.
15. [15] Rønne E, Pappot H, Grøndahl-Hansen J et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89:576-581.
16. [16] Nielsen LS, Kellerman GM, Behrendt N, Picone R, Danø K, Blasi F. A 55000-60000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988;263:2358-2363.
17. [17] Chucholowski N, Schmitt M, Rettenberger P et al. Flow cytometric analysis of the urokinase receptor (uPA-R) on tumor cells by fluorescent uPA-ligand or monoclonal antibody #3936. Fibrinolysis 1992;6(Suppl. 4):95-102.
18. [18] Böyum A. Isolation of mononuclear cell and granulocyte from human blood. Scand J Clin Lab Invest 1967;21(Suppl. 97):77-89.
19. [19] Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF III. Enzyme-linked immunosorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995;86:203-211.
20. [20] Nakakuma H, Nagakura S, Kawaguchi T et al. Increased plasma decay-accelerating factor levels in paroxysmal nocturnal hemoglobinuria. Int J Hematol 1992;55:121-125.
21. [21] Plesner T, Ralfkiaer E, Wittrup M et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994;102:835-841.
22. [22] Ellis V, Pyke C, Eriksen J, Solberg H, Danø K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992;667:13-31.
23. [23] Pyke C, Graem N, Ralfkiaer E et al. Receptor for urokinase is present in tissue-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-1915.
24. [24] Romer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wound. J Invest Dermatol 1994;102:519-522.
25. [25] Pedersen H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-4675.
26. [26] Pyke C, Kristensen P, Ralfkiaer E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-1067.
27. [27] Appella E, Robinson EA, Ullrich SJ et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987;262:4437-4440.
28. [28] Behrendt N, Rønne E, Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem (Hoppe-Seyler) 1995;376:269-279.
29. [29] Cubellis MV, Nolli ML, Cassanig G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986;261:15819-15822.
30. [30] Bajpai A, Baker JB. Evidence for occupancy with endogenous urokinase of urokinase binding sites on human foreskin cells. Biochem Biophys Res Commun 1985;133:994-1000.
31. [31] Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985;82:4939-4943.
32. [32] Cubellis MV, Andreasen PA, Ragno P, Mayer M, Danø K, Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 1989;86:4828-4832.
33. [33] Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989;74:1396-1402.
34. [34] Barnathan ES, Kou A, Rosenfeld L et al. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 1990;265:2865-2872.
35. [35] Lee SW, Ellis V, Dichek DA. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase. J Biol Chem 1994;269:2411-2418.
36. [36] Higazi AAR, Mazar A, Wang J et al. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 1996;87:3545-3549.
37. [37] Cubellis MV, Wun T-C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-1085.
38. [38] Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA:PAI-1 complexes and is essential for embryo implantation. Cell 1992;71:411-421.
39. [39] Low MG. The glycosyl-phosphatidylinositol anchor of membrane proteins. Biochim Biophys Acta 1989;988:427-454.
40. [40] Nykjaer A, Petersen CM, Moller B et al. Purified α2-macroglobulin receptor/LDL receptor-related protein binds urokinase:plasminogen activator inhibitor type 1 complex. J Biol Chem 1992;267:14543-14546.